February 12, 2019 09:06 AM EST

In the battle against kidney cancer, Merck's keystone immunotherapy Keytruda edges in front

Merck $MRK may not just have a leg up over Bristol-Myers Squibb $BMY in the lucrative field of lung cancer. It looks like the company’ …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In the bat­tle against kid­ney can­cer, Mer­ck­'s key­stone im­munother­a­py Keytru­da edges in front